NEW YORK (GenomeWeb News) — Shares in Vermillion, formerly Ciphergen Biosystems, were up 9.3 percent, or $.08, at $.94 in mid-afternoon trading today after the company published findings showing how a protein biomarker may help diagnose peripheral artery disease.
 
Specifically, the findings suggest that the biomarker, called beta-2 microglobulin, is elevated in patients with PAD and that the level of the protein is correlated with the severity of the disease.
 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York City medical examiner is overseeing an effort to identify missing persons using DNA, according to the Associated Press.

Nobel laureate Günter Blobel has died at 81, the New York Times reports.

In PNAS this week: mouse model of genetically induced emphysema, gene expression signatures of circulating melanoma cells, and more.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.